Yung‐Luen Yu

3.3k citations

80 papers · 2.6k indexed · 1 hit paper · h-index 28

Molecular Biology top 5%
Cancer Research top 2%
Oncology top 5%
Pulmonary and Respiratory Medicine top 5%
Immunology top 10%

Co-authors: Ruey‐Hwang Chou Ling‐Chu Chang Wei-Chao Chang Shuen‐Ei Chen Mien‐Chie Hung Giou‐Teng Yiang Longfei Huo Wei‐Chien Huang
Topics: Epigenetics and DNA Methylation (12 papers)MicroRNA in disease regulation (9 papers)RNA modifications and cancer (7 papers)
Cited by: Cancer Research Molecular Biology Oncology
Journals: Proceedings of the National Academy of Sciences Journal of Biological Chemistry The Journal of Experimental Medicine
Partner nations: Taiwan United States Japan

In The Last Decade

Yung‐Luen Yu

77 papers receiving 2.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Heme oxygenase-1 mediates BAY 11–7085 induced ferroptosis

2017 443 citations Ling‐Chu Chang, Shuen‐Ei Chen et al. Cancer Letters profile →

Peers

Countries citing papers authored by Yung‐Luen Yu

Since Specialization

Citations

This map shows the geographic impact of Yung‐Luen Yu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yung‐Luen Yu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yung‐Luen Yu more than expected).

Fields of papers citing papers by Yung‐Luen Yu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yung‐Luen Yu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yung‐Luen Yu. The network helps show where Yung‐Luen Yu may publish in the future.

Co-authorship network of co-authors of Yung‐Luen Yu

This figure shows the co-authorship network connecting the top 25 collaborators of Yung‐Luen Yu. A scholar is included among the top collaborators of Yung‐Luen Yu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yung‐Luen Yu. Yung‐Luen Yu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Exploration of shared biomarkers and mechanisms in systemic lupus erythematous and lung cancer via bioinformatics analysis 2025 ·Journal of Translational Autoimmunity ·(unknown),(unknown),Yung‐Luen Yu	0
2	The clinical impact of galectin-8 in drug resistant breast cancer 2025 ·Journal of Cancer ·(unknown),Jiayan Wu,Chun Pang,Ruey‐Hwang Chou,Yung‐Luen Yu	2
3	The in vitro and in vivo skin‐whitening activity of Ectoine through enhanced autophagy in melanocytes and keratinocytes and zebrafish model 2025 ·BioFactors ·(unknown),(unknown),(unknown),(unknown),Sudhir Pandey,Hsueh‐Wei Chang,Hsin‐Ling Yang,You‐Cheng Hseu,Yung‐Luen Yu	0
4	Capsanthin inhibits migration and reduces N-linked glycosylation of PD-L1 via the EZH2-PD-L1 axis in triple-negative breast cancer brain metastasis 2025 ·Cell Death Discovery ·(unknown),Jiayan Wu,Liang‐Chih Liu,Yung‐Luen Yu	3
5	Alpha-mangostin alleviate renal interstitial fibrosis via suppression of TGF-β1/Smad/ERK signaling axis in vitro and in vivo 2023 ·Biochemical Pharmacology ·(unknown),Yung‐Luen Yu,(unknown),(unknown),(unknown),(unknown),Jen‐Pi Tsai,Yi‐Hsien Hsieh	10
6	EZH2-mediated epigenetic silencing of tumor-suppressive let-7c/miR-99a cluster by hepatitis B virus X antigen enhances hepatocellular carcinoma progression and metastasis 2023 ·Cancer Cell International ·(unknown),(unknown),Chia‐Jui Yen,Jiayan Wu,Li‐Yuan Bai,Yung‐Luen Yu	9
7	The interconnected roles of TRIM21/Ro52 in systemic lupus erythematosus, primary Sjögren’s syndrome, cancers, and cancer metabolism 2023 ·Cancer Cell International ·(unknown),Yung‐Luen Yu	9
8	The Function of the Mutant p53-R175H in Cancer 2021 ·Cancers ·(unknown),(unknown),Yuheng Lin,(unknown),Dung‐Fang Lee,Yung‐Luen Yu	65
9	Antiproliferative and Antimetastatic Effects of Praeruptorin C on Human Non–Small Cell Lung Cancer through Inactivating ERK/CTSD Signalling Pathways 2020 ·Molecules ·(unknown),(unknown),(unknown),Yung‐Luen Yu,(unknown),Chung‐Jung Liu,Yi‐Hsien Hsieh	16
10	Anti-cancer therapeutic benefit of red guava extracts as a potential therapy in combination with doxorubicin or targeted therapy for triple-negative breast cancer cells 2020 ·International Journal of Medical Sciences ·(unknown),(unknown),(unknown),Chien‐Sheng Chen,(unknown),Shu‐Yu Lin,Giou‐Teng Yiang,Yung‐Luen Yu	16
11	Heme oxygenase-1 mediates BAY 11–7085 induced ferroptosisbreakdown → 2017 ·Cancer Letters ·Ling‐Chu Chang,(unknown),Shuen‐Ei Chen,Yung‐Luen Yu,Ruey‐Hwang Chou,Wei-Chao Chang	443
12	NLRP3 inflammasome: Pathogenic role and potential therapeutic target for IgA nephropathy 2017 ·Scientific Reports ·(unknown),Kuo-Feng Hua,Ann Chen,(unknown),Wen‐Shiang Chen,(unknown),Ching‐Liang Chu,Yung‐Luen Yu,(unknown),Shuk‐Man Ka	68
13	The newly synthesized 2-arylnaphthyridin-4-one, CSC-3436, induces apoptosis of non-small cell lung cancer cells by inhibiting tubulin dynamics and activating CDK1 2015 ·Cancer Chemotherapy and Pharmacology ·Ling‐Chu Chang,Yung‐Luen Yu,(unknown),Yung‐Yi Cheng,Ruey‐Hwang Chou,Min‐Tsang Hsieh,Hui-Yi Lin,Hsin‐Yi Hung,Li-Jiau Huang,Yang‐Chang Wu,Sheng-Chu Kuo	17
14	Impact of EZH2 Polymorphisms on Urothelial Cell Carcinoma Susceptibility and Clinicopathologic Features 2014 ·PLoS ONE ·Yung‐Luen Yu,(unknown),Ming-Ju Hsieh,(unknown),Po-Hui Wang,(unknown),Shun‐Fa Yang	11
15	Lapatinib-Mediated Cyclooxygenase-2 Expression via Epidermal Growth Factor Receptor/HuR Interaction Enhances the Aggressiveness of Triple-Negative Breast Cancer Cells 2013 ·Molecular Pharmacology ·Te‐Chun Hsia,Chih‐Yen Tu,Yun‐Ju Chen,Ya-Ling Wei,(unknown),(unknown),(unknown),(unknown),Ming‐Hsin Yeh,Chia-Jui Yen,Yung‐Luen Yu,Tzung-Chi Huang,Chih‐Yang Huang,Mien‐Chie Hung,Wei‐Chien Huang	34
16	The NS3 protease and helicase domains of Japanese encephalitis virus trigger cell death via caspase-dependent and -independent pathways 2013 ·Molecular Medicine Reports ·Giou‐Teng Yiang,(unknown),(unknown),(unknown),(unknown),Yung‐Luen Yu	21
17	Lapatinib–induced NF-kappaB activation sensitizes triple-negative breast cancer cells to proteasome inhibitors 2013 ·Breast Cancer Research ·Yun‐Ju Chen,Ming‐Hsin Yeh,(unknown),Ya-Ling Wei,(unknown),(unknown),(unknown),Chih‐Yen Tu,Chia‐Hung Chen,Te‐Chun Hsia,(unknown),Shu-Hui Liu,Yung‐Luen Yu,Wei‐Chien Huang	61
18	Slug Confers Resistance to the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor 2010 ·American Journal of Respiratory and Critical Care Medicine ·(unknown),Meng-Feng Tsai,Kang‐Yi Su,(unknown),(unknown),Sung‐Liang Yu,Yung‐Luen Yu,Chou-Chin Lan,James Chih‐Hsin Yang,(unknown),Chin-Pyng Wu,Jin‐Yuan Shih,Pan‐Chyr Yang	146
19	Isochaihulactone protects PC12 cell against H2O2 induced oxidative stress and exerts the potent anti-aging effects in D-galactose aging mouse model 2010 ·Acta Pharmacologica Sinica ·Sung‐Liang Yu,(unknown),Yung‐Luen Yu,(unknown),(unknown),(unknown),Tzong‐Der Way,Giou-Teng Yiang,(unknown),De‐Chuan Chan,Horng‐Jyh Harn,(unknown)	17
20	CREB Is One Component of the Binding Complex of the Ces-2/E2A-HLF Binding Element and Is an Integral Part of the Interleukin-3 Survival Signal 2001 ·Molecular and Cellular Biology ·Wannhsin Chen,Yung‐Luen Yu,(unknown),(unknown),Jyh-Rong Chao,(unknown),(unknown),Chang‐Jen Huang,Ming‐Zong Lai,Hsin‐Fang Yang‐Yen,J. J. Yen	35

About Yung‐Luen Yu

Yung‐Luen Yu is a scholar working on Cancer Research, Molecular Biology and Pharmacology, having authored 80 papers that have together received 2.6k indexed citations. Recurring topics across this work include Epigenetics and DNA Methylation (12 papers), MicroRNA in disease regulation (9 papers) and RNA modifications and cancer (7 papers). The work is most often cited by research in Cancer Research (701 citations), Molecular Biology (1.7k citations) and Oncology (592 citations). Yung‐Luen Yu has collaborated with scholars based in Taiwan, United States and Japan. Frequent co-authors include Ruey‐Hwang Chou, Ling‐Chu Chang, Wei-Chao Chang, Shuen‐Ei Chen, Mien‐Chie Hung, Giou‐Teng Yiang, Longfei Huo, Wei‐Chien Huang, Woei‐Cherng Shyu and Chen‐Shiou Wu. Their work appears in journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and The Journal of Experimental Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact